Abstract
Seasonal and perennial allergic conjunctivitis are IgE-mediated, hypersensitivity ophthalmic conditions characterized by ocular pruritus, epiphora, and hyperemia. Proper diagnosis is usually made clinically based on history and physical examination. Diagnostic procedures are rarely necessary. Non-pharmacological measures, such as environmental modification and proper eye care, should be considered for all patients with allergic conjunctivitis. Pharmacological interventions may also be required. Milder cases can be treated with short-term topical ophthalmic therapy such as a decongestant/antihistamine combination, a mast cell stabilizer, or a multi-action agent. Moderate to severe cases may require longer usage of the above agents or the addition of an oral antihistamine. Refractory cases may necessitate the use of topical ophthalmic corticosteroids and/or immunotherapy. Despite all the available therapeutic agents, there continues to be a constant need to discover more effective ways to treat seasonal and perennial allergic conjunctivitis. This review article also discusses recent patents related to the field.
Keywords: Seasonal and perennial allergic conjunctivitis, ocular pruritus, epiphora, hyperemia, pharmacotherapy, immunotherapy
Recent Patents on Inflammation & Allergy Drug Discovery
Title: Seasonal and Perennial Allergic Conjunctivitis
Volume: 3 Issue: 2
Author(s): Alex H.C. Wong, Stefani S.N. Barg and Alexander K.C. Leung
Affiliation:
Keywords: Seasonal and perennial allergic conjunctivitis, ocular pruritus, epiphora, hyperemia, pharmacotherapy, immunotherapy
Abstract: Seasonal and perennial allergic conjunctivitis are IgE-mediated, hypersensitivity ophthalmic conditions characterized by ocular pruritus, epiphora, and hyperemia. Proper diagnosis is usually made clinically based on history and physical examination. Diagnostic procedures are rarely necessary. Non-pharmacological measures, such as environmental modification and proper eye care, should be considered for all patients with allergic conjunctivitis. Pharmacological interventions may also be required. Milder cases can be treated with short-term topical ophthalmic therapy such as a decongestant/antihistamine combination, a mast cell stabilizer, or a multi-action agent. Moderate to severe cases may require longer usage of the above agents or the addition of an oral antihistamine. Refractory cases may necessitate the use of topical ophthalmic corticosteroids and/or immunotherapy. Despite all the available therapeutic agents, there continues to be a constant need to discover more effective ways to treat seasonal and perennial allergic conjunctivitis. This review article also discusses recent patents related to the field.
Export Options
About this article
Cite this article as:
Wong H.C. Alex, Barg S.N. Stefani and Leung K.C. Alexander, Seasonal and Perennial Allergic Conjunctivitis, Recent Patents on Inflammation & Allergy Drug Discovery 2009; 3 (2) . https://dx.doi.org/10.2174/187221309788489733
DOI https://dx.doi.org/10.2174/187221309788489733 |
Print ISSN 1872-213X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-2710 |
Related Articles
-
Update on the Medical Treatment of Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) Surgical Treatment of Neonatal Mastitis by Periareolar Drainage
Current Pediatric Reviews Technological Barriers in the Use of Electrochemical Microsensors and Microbiosensors for in vivo Analysis of Neurological Relevant Substances
Current Neuropharmacology Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan
Current Drug Delivery L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Current Medicinal Chemistry Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews